Hernández PC, Lembe MFD, Benavides PY, Echavarria PS, Quintero SY, Concepción FY, Macia PI, Romero GA

Language: Spanish
References: 29
Page: 1-17
PDF size: 335.54 Kb.

ABSTRACT

Introduction: The PML-ATO protocol for the treatment of promyelocytic leukemia has obtained excellent results, achieving high overall survival rates and the possible healing of patients. Two cardiotoxic drugs are used in the induction process: anthracyclines and arsenic trioxide, whereas during consolidation patients receive a high dose of arsenic.
Objective: Evaluate the late cardiotoxicity in patients with promyelocytic leukemia treated by the PML-ATO protocol.
Methods: An observational prospective longitudinal descriptive study was conducted of 20 patients treated with the PML-ATO protocol and followed-up in outpatient consultation from January to July 2019. More than two years had elapsed since the patients received the cardiotoxic drugs. A review was carried out of the patients' medical records and echocardiographic determination was made of left ventricular ejection fraction and overall longitudinal deformity.
Results: Men and women presented the same frequency; mean age was 41.5 ± 11.0 years. During induction, arsenic was suspended in less than half the patients due to corrected QT elevation. In most it was only suspended for one or two days. Most patients had left ventricular ejection fraction values between 61% and 70%, whereas overall longitudinal deformity was - 24% - 22%.
Conclusions: In the patients studied, cardiac function was not affected by the time elapsed since arsenic trioxide administration or the dose received.

REFERENCES

1. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, et al. Proposals for the Classification of the Acute Leukaemias. Br J Haematology.1976;33:451-8.

2. de la Serna J, Montesinos P, Vellenga E, Rayón C, Parody R, León A, et al. Causes and Prognostic Factors of Remission Induction Failure in Patients with Acute Promyelocytic Leukemia Treated with All-Trans Retinoic Acid and Idarubicin. Blood. 2008;111(7):3395-402.

3. Nowak D, Stewart D, Koeffler HP. Differentiation therapy of leukemia: 3 decades of development. Blood. 2009;113(16):3655-65.

4. Adès L, Thomas X, Guerci Bresler A, Raffoux E, Spertini O, Vey N, et al. Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group. Haematologica 2018; 103(12):2033-9.

5. Huang M, Ye Y, Chen S, Chai J, Lu J, Zhoa L, et al. Use of All-Trans Retinoic Acid in the Treatment of Acute Promyelocytic Leukemia. Blood.1988;72(2):567-72.

6. Baljevic M, Park JH, Stein E, Douer Dm Altman JKm Tallman MS. Curing All Patients with Acute Promyelocytic Leukemia: Are We There Yet? Hematol Oncol Clin North Am 2011;25(6):1215

7. Zhou GB, Zhang J, Wang ZY, Chen SJ, Chen Z. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy. Phil Trans R Soc B 2007;362:959-71.

8. Hernández Ramírez P, Carnot Uría J, Dorticós Balea E, Espinosa Martínez E, González Otero A, Hernández Pérez G, et al. Tratamiento de la leucemia promielocítica con ácido retinoico. Rev Cub Hematol Inmunol Hemoter [Internet]. 1995 [acceso 26/07/2016];11(1): Disponible en: Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/568/281

9. Testi AM, Biondi A, Lo Coco F, Moleti ML, Giona F, Vignetti M, et al. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Blood. 2005;106(2):447-53.

10. Mi J-O, Li J-M, Shen S J, Chen S J, Chen Z. How to manage acute promyelocytic leukemia. Leukemia 2012;26(8):1743-51.

11. Hernández Padrón C, Machín García S, Gómez Carril M, Ramón Rodriguez L, Losada Buchillón R, Agramonte Llanes O, et al. Uso del trióxido de arsénico en el tratamiento de la leucemia promielocítica en recaída Rev Cubana Hematol Inmunol Hemoter [Internet]. 2007 [acceso 28/01/2020];23(1). Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892007000100009&lng=es .

12. Diverio D, Rossi V, Avvisati G, De Santis S, Pistilli A, Pane F, et al. Early Detection of Relapse by Prospective Reverse Transcriptase-Polymerase Chain Reaction Analysis of the PML/RARa Fusion Gene in Patients with Acute Promyelocytic Leukemia Enrolled in the GIMEMA-AIEOP Multicenter ''AIDA'' Trial. Blood. 1998;92(3):784-89.

13. Sanz MA, Grimwade D, Tallman MS, Lowenberg B, Fenaux P, Estey EH, et al. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European Leukemia Net 2009 Blood. 2009 Feb 26;113(9):1875-91. DOI: https://10.1182/blood-2008-04-150250

14. Hernández-Padrón C, Dorticós-Balea E, Machín-García S, Menéndez-Veitía A, González-Otero A, Avila-Cabrera O, et al. Leucemia promielocítica de reciente diagnóstico. Tratamiento con trióxido de arsénico de producción nacional. (ARSENIN(r)). Rev Cub Hematol, Inmunol Hemoter [Internet]. Dic 2014 [acceso 28/01/2020];30(4):346-59. Disponible en: Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0864-02892014000400006&lng=es .

15. Espinola Zavaleta N, Lupi Herrera E. El papel del ecocardiograma en la valoración de la cardiotoxicidad por quimioterapia An Med (Mex).2015;60(3):199-205.

16. Ruiz-Mori E, Ayala-Bustamante L, Burgos-Bustamante J, Pacheco Román C. Cardiotoxicidad por quimioterapia en el Instituto Nacional de Enfermedades Neoplásicas 2012-2016. Horiz Med. 2017;17(3):24-8.

17. Griffin J D. Blood's 70th anniversary: arsenic - from poison pill to magic bullet. Blood. 2016;127(14):1729-30.

18. Suárez Beyríes LC, Noa Tamayo Y, Rodríguez Reyes I, Hernández Galano G, de la Uz Ruesga BO. Tratamiento con trióxido de arsénico en pacientes con leucemia promielocítica aguda. MEDISAN. 2014;18(1):25-33.

19. Daver N, Kantarjian H, Marcucci G, Pierce S, Brandt M, Dinardo C, et al. Clinical Characteristics and Outcomes in Patients with Acute Promyelocytic Leukaemia and Hyperleucocytosis. Br J Haematol. 2015 Mar;168(5):646-53. DOI: https://10.1111/bjh.13189

20. Anis MAA, Khan MA, Afrose S. A Prospective Study of Effectiveness of ATO in Remission Induction of APL Chattagram Maa-O-Shishu Medical College Journal. 2015;14(2):5-10.

21. Lengfelder E, Lo-Coco F, Ades L, Sanz M. Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European Leukemia Net. Leukemia. 2015;29:1084-91.

22. Islam AKMM, Ali M, Anis MAA, Aziz AM, Siddika SS, Haque S, et al. Treatment Outcome of Newly Diagnosed Acute Promyelocytic Leukaemia by All-Trans Retinoic Acid Followed by Arsenic Tri-Oxide. Haematol J Bangladesh.2018;2(1):3-7.

23. Perrino C, Schiattarella G, Magliulo F, Ilardi F, Carotenuto G, Gargiulo G, et al. Cardiac side effects of chembibrapy: state of art and strategies for a correct management Curr Vasc Pharmacol. 2014;12(1):106-16.

24. Ruiz E, Ayala L, Burgos J. Insuficiencia Cardíaca por quimioterapia. Rev Soc Peruana Med Int. 2016;29(2):59-64.

25. Plana JC, Galderisi M, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2014;24(6):911-39.

26. Bloom M, Hamo C, Cardinale D, Ky B, Nohria A, Baer L, et al. Cancer Therapy-Related Cardiac Dysfunction and Heart Failure. Circ Heart Fail. 2016;9(2):e002843.

27. Mandan V, Shyamsunder P, Han L. Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia. 2016;30:1672-81.

28. Wise J. Adult survivors of childhood cancer are at high risk of cardiac abnormalities, study finds. BMJ. Jan 2016;352:h7026. DOI: https://10.1136/bmj.h7026

29. Morales Yera MY, Sierra Pérez L, Triana Díaz A. Cardiotoxicidad inducida por quimioterapia. CorSalud ene-mar 2018; 10(1):68-77.